.
New Delhi, April 26 (MondayMirror.com) The Drugs Controller General of India (DCGI) on Tuesday approved the restricted emergency use authorisation (EUA) to Bharat Biotech’s Covaxin for children between the age of 6-12 years, sources said.
The DGCI has asked vaccine manufacturer to submit safety data including the data on adverse event with due analysis every 15 days for the first two months and monthly thereafter upto 5 months, said the source familiar with the development.
This development comes after the Subject Expert Committee (SEC) discussed recommendations for the restricted emergency use of Covaxin in children aged between 2-12 years.
However, the SEC, after a meeting on Thursday, had recommended restricted emergency use of Biological E’s Covid-19 vaccine, Corbevax, in children aged 5-12 years.
Source: IANS
Small Wonders School, Mohali, celebrated its Annual Day with enthusiasm and vibrant performances under the…
Velvet Clarks Exotica, Zirakpur celebrated its 12th Annual Day with great enthusiasm, joy, and team…
Artificial Intelligence (AI) must serve as a tool to enhance human intelligence rather than replace…
“My main objective is to empower needy women by training them in crafts like hand…
Their publication received the 2026 Best Case Report – Silver Award at Plastic Surgery The…
Michael Jackson's extraordinary musical legacy is returning to the spotlight, but this time, the conversation…